Evaluation of Protein Loading on Measurement of Renal Reserve

Inclusion Criteria: To be eligible for study entry, all participants must satisfy all of the following criteria: 1. Age \> 18 years - male or female 1. Eligible female non-pregnant participants who are either not of child-bearing potential or willing to use adequate contraception during the trial 2. Males must be willing to practice abstinence or utilize adequate contraception from dosing day to at least 7 days post-dose 3. For women of child-bearing potential, the participant should have a negative pregnancy test, and agrees to one of the following acceptable contraceptive methods used consistently and correctly i.e. abstinence, oral contraceptive either combined or progesterone alone; injectable progesterone, implants of levonorgestrel, estrogenic vaginal ring, percutaneous contraceptive patches, IUD device or system or male partner sterilization 4. Men will not donate sperm during the study and for 1 month following the last dose of study drug 2. Participants who are capable of directly providing informed consent and who can comply with the requirements and restrictions required by the protocol 3. eGFR \>30 mL/min/1.73 m\^2 4. Capable of fasting for at least 8 hours prior to the evaluation day Exclusion Criteria: 1. Current use of renin-angiotensin-aldosterone system inhibitors (RAASi) including angiotensin-receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACE-inhibitors) or direct renin inhibitors that can't be stopped at least 5 half-lives prior to the study day. 2. Current use of sodium-glucose cotransporter-2 (SGLT2) inhibitors such as bexaglifloxin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin or others that can't be stopped at least 5 half-lives prior to the study day. 3. Currently taking any drug classified as a sympathomimetic drug such as dobutamine, dopamine, norepinephrine, epinephrine, isoproterenol or others. 4. Current over the counter use of cold medications containing ephedrine or weight loss drugs containing ephedra alkaloids 5. Current history of drug use involving cocaine, mephedrone, amphetamines or methamphetamine 6. The participant has participated in a clinical trial and has received an investigational product within the following time ranges: prior to the first dosing day in the current study: either 30 days or 5 half-lives of the investigational product (whichever duration is longer). 7. History of skin sensitivity to adhesives (e.g. Band-Aids, surgical tape) 8. History of severe allergic hypersensitivity reactions (unacceptable adverse events) or anaphylactoid reaction to any allergen including drugs, Lumitrace or other related products (intolerance to a drug is not considered a drug allergy). 9. Any characteristics which, in the opinion of the investigator, makes the participant a poor candidate for participation in the clinical trial. 10. Significant scarring, tattoos or alterations in pigmentation on the sternum or other sensor location testing areas that would alter sensor readings versus other areas of the skin 11. Use of tanning sprays, tanning products etc. on the upper chest within 2 weeks of dosing day 12. Use make-up, lotions, Vaseline or other products on the upper chest on the day prior to or the day of assessments 13. Any serious or uncontrolled medical disorder, active infection, physical exam finding, laboratory finding, or psychiatric condition that in the opinion of the investigator would limit the subjects' ability to complete study requirements or may put the subject at increased risk or compromise the interpretability of study results. 14. Participants with positive pregnancy test